Iowa E-Cigarette Law Challenged: Industry Claims New Rules Will Destroy the Industry and Violate FDA Enforcement Discretion

Aug.28.2025
E-cigarette sellers and buyers asked the Eighth Circuit Court to keep blocking Iowa's HF 2677 bill. The bill would make all e-cigarettes sold in Iowa get FDA approval. They say the federal Food, Drug, and Cosmetic Act blocks this law, as it steps on FDA's toes by adding penalties where FDA didn't act. If the bill goes through, businesses might close and people could lose tools to quit smoking.

Key points:

 

·Legal Conflict: Iowa state law requires e-cigarettes to obtain FDA authorization, but the FDA is using a case-by-case approach, allowing some products to be sold without authorization. 

·Federal Preemption: A lower court has ruled that the state law is preempted by federal law, leading the state government to appeal to the Eighth Circuit Court of Appeals. 

·Industry Impact: E-cigarette groups argue that enforcement of the law would result in businesses closing and consumers being unable to access smoking cessation tools. 

·Standing: The state government questions the standing of e-cigarette groups to sue, arguing that their request violates federal law, while the groups counter that the FDA's enforcement discretion should not be determined by the state. 

·Legal Outlook: The outcome of the case will impact the regulation of the e-cigarette industry and consumer rights, with much attention on the ruling from the Eighth Circuit Court of Appeals.

 


 

According to a report from Law360 on August 27, a group of e-cigarette sellers and buyers are urging the Eighth Circuit Court not to overturn an injunction blocking the enforcement of a law in Iowa that requires e-cigarettes sold in the state to be authorized by the US Food and Drug Administration (FDA). They argue that the district court found that the law was preempted by federal law.

 

In the submitted complaint, the group led by "Iowans for Alternatives to Smoking & Tobacco" countered the state government's appeal, arguing that the new law actually mandates compliance with the Food, Drug, and Cosmetic Act (FDCA), which Congress has authorized the FDA to enforce.

 

According to the complaint, the FDA has chosen to review e-cigarette products on a case-by-case basis within its discretion and has allowed some products to continue being sold on the market without premarket authorization. Iowa laws impose civil penalties on the FDA for choosing not to enforce its regulations in certain areas.

 

The complaint also points out that while the state government can implement other restrictions that are not preempted by federal law, such as banning certain flavors or limiting nicotine concentrations, the incorporation and reference of the Food, Drug, and Cosmetic Act in this law means it is preempted by federal law.

 

Furthermore, according to the complaint, the provisions of this law would be rendered ineffective without the support of the Family Smoking Prevention and Tobacco Control Act, placing it entirely within the scope of federal preemption.

 

The lawsuit challenges HF 2677, a law that grants the Iowa Department of Revenue the power to fine retailers, wholesalers, and manufacturers of e-cigarettes who have not obtained FDA authorization for their electronic nicotine delivery system products.

 

United States District Judge Stephanie M. Rose blocked the enforcement of the law in May, finding it to be preempted because it infringed upon the FDA's authority to regulate e-cigarettes under the Food, Drug, and Cosmetic Act.

 

The state government has appealed to the Eighth Circuit Court and argued in a July filing that e-cigarette stakeholders and other plaintiffs do not have standing to sue because their lawsuit is essentially requesting continued violation of federal law. Additionally, the state government also pointed out that historically states have been allowed to regulate tobacco sales in instances where federal law does not preempt.

 

In the complaint filed on August 26, e-cigarette stakeholders also defended their standing to sue, arguing that the state government incorrectly likened the nature of their actual harm to drug traffickers and users. Because the FDA is exercising its enforcement discretion, whether the sale or use of e-cigarettes is "illegal" should not be determined by the state of Iowa.

 

The complaint also points out that the e-cigarette company claims that if the HF 2677 bill is enforced, they will be forced to shut down and consumers will be unable to access the devices they use to quit smoking, which has already demonstrated their harm and irreparable losses.

 

These companies further argue that under HF 2677 legislation, they will not only lose sales due to the banned e-cigarette products, but will also be forced to shut down all operations, including those products that are explicitly approved by the FDA.

 

If this law is not prohibited, these companies argue that they can present necessity as a defense in any enforcement action against them, therefore they have reason to challenge the law in anticipation of enforcement.

 

The case is filed under docket number 25-2087 at the United States Eighth Circuit Court of Appeals.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07